Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.74 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.74 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gamma-Cyclodextrin SCHEMBL20998969 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23188251 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL21134960 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL25455463 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25455476 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL24109285 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL24109286 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL23188277 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL20533920 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Gamma-Cyclodextrin SCHEMBL25455531 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108408863-A | Flocculating agent and preparation method thereof | 湖南辰砾新材料有限公司 | 2018-08-17 | — | — | CN | claimed |
| CN-117899084-A | Pharmaceutical composition, preparation, metolachlor Zong Donggan powder preparation, preparation method and application thereof | 西安泰可益康生物科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240123021-A1 | PHARMACEUTICAL COMPOSITIONS | EXTROVIS AG (CH) | 2024-04-18 | — | — | US | disclosed |
| CN-117679369-A | Glutathione liposome preparation and preparation method thereof | 卓和药业集团股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023214204-A1 | PHARMACEUTICAL COMPOSITION FOR RESTORING PHYSIOLOGICAL PROCESSES AND CELLS OF ORGANISM | KURKAYEV ABDULA (HU) | 2023-11-09 | — | — | WO | disclosed |
| EP-4272745-A1 | PHARMACEUTICAL COMPOSITION FOR RESTORING PHYSIOLOGICAL PROCESSES AND CELLS OF ORGANISM | Kurkayev, Abdula (HU) | 2023-11-08 | — | — | EP | disclosed |
| CN-115957332-B | Hyaluronidase-stable breinox Long Nami crystal and preparation method and application thereof | 北京华睿鼎信科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116549733-A | Decellularized vascular stent with anticoagulation and endothelialization promoting functions and preparation method thereof | 新乡医学院 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023126636-A1 | EYE DROP FORMULATION | SEMMELWEIS EGYETEM (HU) | 2023-07-06 | — | — | WO | disclosed |
| EP-4164608-A1 | PHARMACEUTICAL COMPOSITIONS | Extrovis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| WO-2019165349-A1 | METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPß INHIBITORS | AERPIO THERAPEUTICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-109674744-A | Stable tirofiban hydrochloride liquid composition and preparation method thereof | 成都欣捷高新技术开发股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-3411047-A1 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | Czap Research And Development, LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| CN-108883125-A | Controlled release and layered cyclodextrin inclusion complex vehicles | 西泽普研究与发展有限责任公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108408863-A | Flocculating agent and preparation method thereof | 湖南辰砾新材料有限公司 | 2018-08-17 | — | — | CN | disclosed |
| WO-2017136775-A1 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC (US) | 2017-08-10 | — | — | WO | disclosed |
| CN-101463136-A | Method for preparing beta-cyclodextrin cross-linked polymer | UNIV NINGBO TECHNOLOGY (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20080029455-A1 | Separation Methods | NOVEXIN LIMITED (GB) | 2008-02-07 | — | — | US | disclosed |
| EP-1689769-A1 | SEPARATION METHODS | Novexin Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005047310-A1 | SEPARATION METHODS | NOVEXIN LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123021-A1 | PHARMACEUTICAL COMPOSITIONS | CETP, PCSK9, LPXN | ALDH1A1 4386/4885TSHR 2401/4885LMNA 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.